Phase 2, Open Label, Randomized, Active Controlled Pilot Study MW-III vs Silver Sulfadiazine Second Degree Thermal Burns

• Status: Not yet recruiting
• Trial end date: 2023-03-12
• Target enrollment: 0
• Participant gender: All

Summary

To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" in second-degree thermal burns

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Skingenix, Inc.
• Treatments: Silver Sulfadiazine; Sulfadiazine

Criteria

Inclusion Criteria:

1. Adults (≥18 years of age) on the day of signing the informed consent

2. Diagnosed with a single second-degree thermal burn:

3. Burn occurrence ≤24 hours prior to study entry

4. Able and willing to give informed consent and comply with study procedures. In the case of a guardian, guardian must provide informed consent on behalf of the subject.

Exclusion Criteria:

1. Patients with the co-existence of full thickness (third-degree) burn wound

2. Multiple second-degree thermal burns

3. Circumferential burns or burns deemed high risk for developing compartment syndrome

4. Target burn wound requiring surgical intervention, such as excision/grafting